1128 related articles for article (PubMed ID: 25974703)
1. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
Bousman CA; Stevenson JM; Ramsey LB; Sangkuhl K; Hicks JK; Strawn JR; Singh AB; Ruaño G; Mueller DJ; Tsermpini EE; Brown JT; Bell GC; Leeder JS; Gaedigk A; Scott SA; Klein TE; Caudle KE; Bishop JR
Clin Pharmacol Ther; 2023 Jul; 114(1):51-68. PubMed ID: 37032427
[TBL] [Abstract][Full Text] [Related]
3. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
Brouwer JMJL; Nijenhuis M; Soree B; Guchelaar HJ; Swen JJ; van Schaik RHN; Weide JV; Rongen GAPJM; Buunk AM; de Boer-Veger NJ; Houwink EJF; van Westrhenen R; Wilffert B; Deneer VHM; Mulder H
Eur J Hum Genet; 2022 Oct; 30(10):1114-1120. PubMed ID: 34782755
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
5. Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.
Probst-Schendzielorz K; Viviani R; Stingl JC
Expert Opin Drug Metab Toxicol; 2015; 11(8):1219-32. PubMed ID: 26028357
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
[TBL] [Abstract][Full Text] [Related]
7. Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers.
Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Koller D; Talegón M; Ovejero-Benito MC; López-Rodríguez R; Cabaleiro T; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 May; 122(5):501-511. PubMed ID: 29136336
[TBL] [Abstract][Full Text] [Related]
8. Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
Ricardo-Silgado ML; Singh S; Cifuentes L; Decker PA; Gonzalez-Izundegui D; Moyer AM; Hurtado MD; Camilleri M; Bielinski SJ; Acosta A
BMC Med; 2022 Jul; 20(1):261. PubMed ID: 35879764
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.
Honeycutt DC; Blom TJ; Ramsey LB; Strawn JR; Bruns KM; Welge JA; Patino LR; Singh MK; DelBello MP
J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):42-51. PubMed ID: 38377518
[No Abstract] [Full Text] [Related]
10. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
Hicks JK; Swen JJ; Thorn CF; Sangkuhl K; Kharasch ED; Ellingrod VL; Skaar TC; Müller DJ; Gaedigk A; Stingl JC;
Clin Pharmacol Ther; 2013 May; 93(5):402-8. PubMed ID: 23486447
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
Strawn JR; Poweleit EA; Ramsey LB
J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
[No Abstract] [Full Text] [Related]
12. PharmGKB summary: venlafaxine pathway.
Sangkuhl K; Stingl JC; Turpeinen M; Altman RB; Klein TE
Pharmacogenet Genomics; 2014 Jan; 24(1):62-72. PubMed ID: 24128936
[No Abstract] [Full Text] [Related]
13. A cross-sectional study of the relationship between CYP2D6 and CYP2C19 variations and depression symptoms, for women taking SSRIs during pregnancy.
Hippman C; Slomp C; Morris E; Batallones R; Inglis A; Carrion P; Brain U; Higginson M; Wright GEB; Balneaves LG; Ryan D; Nislow C; Ross CJD; Gaedigk A; Oberlander TF; Austin J
Arch Womens Ment Health; 2022 Apr; 25(2):355-365. PubMed ID: 34231053
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
Hicks JK; Sangkuhl K; Swen JJ; Ellingrod VL; Müller DJ; Shimoda K; Bishop JR; Kharasch ED; Skaar TC; Gaedigk A; Dunnenberger HM; Klein TE; Caudle KE; Stingl JC
Clin Pharmacol Ther; 2017 Jul; 102(1):37-44. PubMed ID: 27997040
[No Abstract] [Full Text] [Related]
15. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes.
Berle JØ; Steen VM; Aamo TO; Breilid H; Zahlsen K; Spigset O
J Clin Psychiatry; 2004 Sep; 65(9):1228-34. PubMed ID: 15367050
[TBL] [Abstract][Full Text] [Related]
16. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
[TBL] [Abstract][Full Text] [Related]
17. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
Ji Y; Schaid DJ; Desta Z; Kubo M; Batzler AJ; Snyder K; Mushiroda T; Kamatani N; Ogburn E; Hall-Flavin D; Flockhart D; Nakamura Y; Mrazek DA; Weinshilboum RM
Br J Clin Pharmacol; 2014 Aug; 78(2):373-83. PubMed ID: 24528284
[TBL] [Abstract][Full Text] [Related]
18. Completed suicides of citalopram users-the role of CYP genotypes and adverse drug interactions.
Rahikainen AL; Vauhkonen P; Pett H; Palo JU; Haukka J; Ojanperä I; Niemi M; Sajantila A
Int J Legal Med; 2019 Mar; 133(2):353-363. PubMed ID: 30173302
[TBL] [Abstract][Full Text] [Related]
19. Genotyping of patients treated with selective serotonin reuptake inhibitors.
Solhaug V; Haslemo T; Kringen MK; Molden E; Dietrichs ES
Tidsskr Nor Laegeforen; 2022 Sep; 142(13):. PubMed ID: 36164782
[TBL] [Abstract][Full Text] [Related]
20. CYP450 genotype and aggressive behavior on selective serotonin reuptake inhibitors.
Ekhart C; Matic M; Kant A; van Puijenbroek E; Schaik RV
Pharmacogenomics; 2017 May; 18(7):613-620. PubMed ID: 28470107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]